Keyword: Johnson & Johnson
Halozyme CEO Helen Torley discusses the company’s two-pronged strategy, what’s up next for the company and why biotechs are filing IPOs earlier.
InVivo Therapeutics, which specializes in spinal cord injuries, names Richard Toselli, M.D., as its president and chief executive.
The partnership brings together J&J’s antibodies and a university’s AAVs in a bid to open up a new frontier in the fight against the disease.
The involvement of the Big Pharmas helped BGV blast past its target, leaving it with €82 million to invest in life science companies in Europe.
XW Laboratories has seen a $17.5 million series B, bumping up its total raise from its first round to $23 million.
Kura Oncology shares are up 75% after the biotech reported hitting the mark in a phase 2 trial of tipifarnib—before the study was fully enrolled.
Johnson & Johnson started 2016 by cutting 3,000 jobs, part of a restructuring move to shore up its lagging medical device businesses. The cuts, in its orthopedics, surgery and cardiovascular units, made up 6% of its medical device employees.
J&J has unveiled another clutch of deals and collaborations with industry and academia.
Actelion has posted mixed late-phase data on its antibiotic cadazolid.
Johnson & Johnson had one of the highest research budgets in dollar terms again last year, although the lowest in percentage terms among its Big Pharma peers, partly because it also has one of the highest revenues.